Erbitux

 


Erbitux is a drug approved to treat colorectal and head & neck cancer. The drug is a chimeric (mouse/human) monoclonal antibody, and functions by inhibiting an epidermal growth factor receptor (EGFR).[citation needed]

Three different companies have a share of Erbitux revenues:

  • Eli Lilly and Company (LLY), which purchased ImClone, the original inventor of Erbitux, in 2008, and sells Erbitux in the U.S. with ImClonne's original partner Bristol-Myers Squibb.
  • Bristol-Myers Squibb Company (BMY), which is ImClone's (now Eli Lilly's) manufacturing and sales partner in the United States.
  • Merck KGaA has the rights to sell Erbitux outside of the U.S.
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki